Epidemiological, virological and clinical characteristics of HBV infection in 223 HIV co-infected patients: a French multi-centre collaborative study

[1]  N. Schnepf,et al.  Epidemiological, virological and clinical characteristics of HBV infection in 223 HIV co-infected patients: a French multi-centre collaborative study , 2013, Virology Journal.

[2]  K. Lacombe,et al.  HIV and viral hepatitis coinfections: advances and challenges , 2012, Gut.

[3]  D. Harnois,et al.  Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B , 2011 .

[4]  Huy Trinh,et al.  Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. , 2011, Gastroenterology.

[5]  R. D. de Man,et al.  Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. , 2010, Gastroenterology.

[6]  A. Mocroft,et al.  Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. , 2010, The Journal of antimicrobial chemotherapy.

[7]  Helen M. Chun,et al.  Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals , 2010, AIDS.

[8]  K. H. Hullsiek,et al.  Epidemiology of Hepatitis B virus infection in a US cohort of HIV-infected individuals during the past 20 years. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  T. Berg,et al.  Long‐term efficacy of tenofovir monotherapy for hepatitis B virus‐monoinfected patients after failure of nucleoside/nucleotide analogues , 2010, Hepatology.

[10]  Norman Gitlin,et al.  Chronic hepatitis B : an update , 2010 .

[11]  M. Balinska.  Hepatitis B vaccination and French Society ten years after the suspension of the vaccination campaign: how should we raise infant immunization coverage rates? , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[12]  J. Phair,et al.  Hepatitis B and long-term HIV outcomes in coinfected HAART recipients , 2009, AIDS.

[13]  B. McMahon,et al.  Chronic hepatitis B: Update 2009 , 2009, Hepatology.

[14]  D. Wendum,et al.  Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients. , 2009, Journal of hepatology.

[15]  Chien-Jen Chen,et al.  Hepatitis B virus DNA levels and outcomes in chronic hepatitis B , 2009, Hepatology.

[16]  Jörg Petersen,et al.  EASL Clinical Practice Guidelines: management of chronic hepatitis B. , 2009, Journal of hepatology.

[17]  V. Soriano,et al.  Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. , 2008, AIDS.

[18]  N. Warner,et al.  The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound , 2008, Hepatology.

[19]  D. Neau,et al.  Prevalence of hepatitis C and hepatitis B infection in the HIV-infected population of France, 2004. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[20]  H. Boot,et al.  Substitution rate of the hepatitis B virus surface gene , 2008, Journal of viral hepatitis.

[21]  R. Bruno,et al.  European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV‐infected adults , 2008, HIV medicine.

[22]  V. de Lédinghen,et al.  Hepatitis B virus genotypes: a retrospective survey in Southwestern France, 1999-2004. , 2007, Gastroenterologie clinique et biologique.

[23]  V. Soriano,et al.  Selection of Hepatitis B Virus (HBV) Vaccine Escape Mutants in HBV-Infected and HBV/HIV-Coinfected Patients Failing Antiretroviral Drugs With Anti-HBV Activity , 2007, Journal of acquired immune deficiency syndromes.

[24]  D. Samuel,et al.  Viral and Clinical Factors associated with Surface Gene Variants among Hepatitis B Virus Carriers , 2007, Antiviral therapy.

[25]  M. Chevallier,et al.  Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  M. Nei,et al.  MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. , 2007, Molecular biology and evolution.

[27]  William M. Lee,et al.  Do HIV care providers appropriately manage hepatitis B in coinfected patients treated with antiretroviral therapy? , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  M. Imamura,et al.  Emergence of a Novel Lamivudine-Resistant Hepatitis B Virus Variant with a Substitution Outside the YMDD Motif , 2006, Antimicrobial Agents and Chemotherapy.

[29]  P. Marcellin,et al.  Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases. , 2006, Journal of hepatology.

[30]  D. Ouzan,et al.  Multicentre study of hepatitis B virus genotypes in France: correlation with liver fibrosis and hepatitis B e antigen status , 2006, Journal of viral hepatitis.

[31]  F. Zoulim,et al.  A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine , 2006, Journal of viral hepatitis.

[32]  F. Carrat,et al.  Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV , 2006, AIDS.

[33]  Giorgio Palù,et al.  Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. , 2005, Journal of hepatology.

[34]  A. Mocroft,et al.  Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort , 2005, AIDS.

[35]  C. Gibbs,et al.  Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. , 2003, Journal of hepatology.

[36]  Michael D. Miller,et al.  The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro , 2003, Journal of Virology.

[37]  V. Soriano,et al.  Distribution of hepatitis B virus genotypes in HIV-infected patients with chronic hepatitis B: therapeutic implications. , 2003, AIDS research and human retroviruses.

[38]  F. Sugauchi,et al.  Hepatitis B e antigen in sera from individuals infected with hepatitis B virus of genotype G , 2002, Hepatology.

[39]  加藤 秀章.  Hepatitis B e antigen in sera from individuals infected with hepatitis B virus of genotype G , 2002 .

[40]  R F Schinazi,et al.  A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. , 2000, The Journal of general virology.

[41]  C. Katlama,et al.  Long‐term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus–infected patients , 1999, Hepatology.

[42]  R. Tubiana,et al.  Effects of Lamivudine on Replication of Hepatitis B Virus in HIV-Infected Men , 1996, Annals of Internal Medicine.

[43]  L. Wang,et al.  Virology Journal , 1966, Nature.